Agreed, the base case was another trial. I had EUA at 40% based on small numbers. It's disappointing but expected. The next trial will be a more informed trial design.
We already have the cells to do a trial. It's all about the OTAT (within the qtr). Thankfully we did not commence a trial early this year. OTAT requirements will also become our MOAT.
I also noted the Biomarkers are still being analyzed, hence the Novartis timeline. I'll have to listen later.
Another 3 months of accumulating for me.
Agreed, the base case was another trial. I had EUA at 40% based...
-
- There are more pages in this discussion • 156 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |